High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1661-1668

  Cagnoni, Pablo J ^a   Nieto, Yago ^a   Shpall, Elizabeth J ^a   Bearman, Scott I ^a   Barón, Anna E ^a   Ross, Maureen ^a   Matthes, Steve ^a   Dunbar, Scott E ^a   Jones, Roy B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; LUNG INJURY; MALE; MASTITIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0031860803     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1661     Document Type: Article

References (32)

1. Swain SM, Lippman ME: Treatment of patients with inflammatory breast cancer, in DeVita V Jr, Hellman S, Rosenberg S (eds): Important Advances in Oncology, Philadelphia, PA, Lippincott, 1989, pp 129-150
2. Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: A review. J Clin Oncol 10:1014-1024,1992
3. Thomas F, Arriagada R, Spielmann M, et al.: Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer 76:2286-2290,1995
4. Peters WP: High-dose chemotherapy for breast cancer, in Harris JR, Lippman ME, Morrow M, et al. (eds): The Breast. Philadelphia, PA, Lippincott-Raven, 1996, pp 735-743
5. Peters WP, Shpall EJ, Jones RB, et al.: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1376,1988
6. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer. A randomized trial.J Clin Oncol 13:2483-2489,1995
7. + peripheral blood progenitors and growth factors on engraftment. J Clin Oncol 12:28-36,1994
8. Jones RB, Matthes S, Dufton C, et al.: Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. Breast Cancer Res Treat 26:5-11-17,1993
9. Hortobagyi GN, Singletary SE, McNeese MD: Treatment of locally advanced and inflammatory breast cancer, in Harris JR, Lippman ME, Morrow M, et al. (eds): Diseases of the Breast. Lippincott-Raven, 1996, pp 585-601
10. Eder JP, Antman K, Peters W, et al.: High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 4: 1592-1597,1986
11. Peters WP, Ross M, Vredenburgh JJ, et al.: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk breast cancer. J Clin Oncol 11:1132-1143,1993
12. Schriber JR, Herzig GP: Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremie syndrome. Semin Hematol34:126-133,1997
13. Brown MS, Simon JH, Stemmer SM, et al.: MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. Am J Neuroradiol 16:2013-2020,1995
14. Jones RB, Matthes S, Shpall EJ, et al.: Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: Pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 85:640-547,1993
15. Ayash L, Elias A, Ibrahim J, et al. High-dose multimodality therapy with autologous stem cell support for stage IIIB breast cancer: The DFCI/BIH experience. Proc Am Soc Clin Oncol 16:90a, 1997 (abstr)
16. Somlo G, Doroshow JH, Forman SJ, et al.: High-dose chemotherapy and stem cell rescue in the treatment of high-risk breast cancer: Prognostic indicators of progression-free and overall survival. J Clin Oncol 15:2882-2893, 1997
17. Adkins DR, Brown RA, Beck E: et al. Outcomes of high-dose chemotherapy and autologous stem cell transplant in stage IIIB inflammatory breast cancer. Proc Am Soc Clin Oncol 16:104a, 1997 (abstr)
18. Palangie T, Mosseri V, Mihura J, et al.: Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 30A-.921-927,1994
19. Koh EH, Buzdar AU, Ames FC, et al.: Inflammatory carcinoma of the breast: Results of a combined modality approach-M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol 27:94-100, 1990
20. Attia-Sobol J, Fernere J-P, Cure H, et al.: Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: Univariate and multivariate analysis. Eur J Cancer 29A: 1081-1088,1993
21. Jones RB, Holland JF, Bhardwaj S, et al.: A phase I-study of intensive-dose Adriamycin for advanced breast cancer. J Clin Oncol 5:172-177,1987
22. Muss HB, Thor AD, Berry DA, et al.: c-erb-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266,1994
23. Perez CA, Fields JN, Fracasso PM, et al.: Management of locally advanced carcinoma of the breast. Cancer 74:466-476, 1994
24. Rouesse J, Friedman S, Sarrazin D, et al.: Primary chemotherapy in the treatment of inflammatory breast carcinoma: A study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 12:1765-1771,1986
25. Thoms WW, McNeese MD, Fletcher GH, et al.: Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 17:739-745,1989
26. Arriagada R, Mouriesse H, Spielmann M, et al.: Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer. Int J Radiat Oncol Biol Phys 19:1207-1210, 1990
27. Maloisel F, Dufour P, Bergerat JP, et al.: Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemo-therapy for inflammatory carcinoma of the breast. Cancer 65:851-855, 1990
28. Chevallier B, Bastit P, Graic Y, et al.: The Centre H. Becquerel studies in inflammatory non-metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer 67:594-601,1993
29. Ellis DL, Teitelbaum SL: Inflammatory carcinoma of the breast: A pathologic definition. Cancer 33:1045-1047,1974
30. Fields JN, Kuske RR, Ferez CA, et al.: Prognostic factors in inflammatory breast cancer. Univariate and multivariate analysis. Cancer 63:1225-1232,1989
31. Carter CL, Allen C, Henson DC: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181-187,1989
32. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF in breast cancer with more than three positive axillary nodes. JAMA 273:542-547,1995